Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele Signs Genotyping Collaboration with Merck, Gives NCI Lab Access to SNP Technology

NEW YORK, May 12 (GenomeWeb News) - ParAllele BioScience has started a pharmacogenomics collaboration with Merck, and has given the National Cancer Institute early access to its SNP genotyping platform, the company said today.

 

Under the agreement with Merck, South San Francisco-based ParAllele will determine genetic variations in a number of genes chosen by Merck using its SNP genotyping platform. Merck will fund the study, which is the second collaboration between the companies.

 

ParAllele's MegAllele SNP genotyping platform will also be used by the Laboratory of Genomic Diversity at NCI-Frederick, an early access customer. The technology does not require the DNA around each SNP to be amplified prior to analysis, according to the company.

 

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.